{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:12:53Z","timestamp":1791112373376,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Regione Autonoma della Sardegna"},{"name":"Michael J Fox Foundation"},{"name":"Prin 2010\u20132011"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuroscience"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.neuroscience.2014.01.042","type":"journal-article","created":{"date-parts":[[2014,1,31]],"date-time":"2014-01-31T08:01:11Z","timestamp":1391155271000},"page":"245-252","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson\u2019s disease"],"prefix":"10.1016","volume":"265","author":[{"given":"E.","family":"Tronci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Fidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Zianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Collu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Stancampiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Gardoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Carta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuroscience.2014.01.042_b0005","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S1474-4422(09)70146-2","article-title":"Memantine in patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial","volume":"8","author":"Aarsland","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0010","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/mds.25366","article-title":"Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia","volume":"28","author":"Bezard","year":"2013","journal-title":"Mov Disord"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0015","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nbd.2003.07.003","article-title":"Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson\u2019s disease","volume":"14","author":"Calon","year":"2003","journal-title":"Neurobiol Dis"},{"issue":"10 Suppl","key":"10.1016\/j.neuroscience.2014.01.042_b0020","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/S1471-1931(00)00018-5","article-title":"Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism","volume":"23","author":"Chase","year":"2000","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0215","article-title":"Amantadine for dyskinesia in Parkinson\u2019s disease","volume":"2","author":"Crosby","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0030","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbr.2007.01.013","article-title":"Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model","volume":"179","author":"Dekundy","year":"2007","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0035","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.tjog.2011.10.004","article-title":"Management of moderate to severe Alzheimer\u2019s disease: focus on memantine","volume":"50","author":"Dominguez","year":"2011","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0220","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S1474-4422(10)70194-0","article-title":"Memantine for patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial","volume":"9","author":"Emre","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0045","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1523\/JNEUROSCI.5326-05.2006","article-title":"A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia","volume":"26","author":"Gardoni","year":"2006","journal-title":"J Neurosci"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0050","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/j.neurobiolaging.2011.06.019","article-title":"Targeting GluN2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias","volume":"33","author":"Gardoni","year":"2012","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0055","first-page":"415","article-title":"Amantadine in Parkinson\u2019s disease: pro and contra","volume":"46","author":"Greulich","year":"1995","journal-title":"J Neural Transm Suppl"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0060","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.neuropharm.2004.11.008","article-title":"Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson\u2019s disease","volume":"48","author":"Hallett","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0065","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/1531-8257(200009)15:5<1016::AID-MDS1042>3.0.CO;2-J","article-title":"The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa","volume":"15","author":"Hana\u011fasi","year":"2000","journal-title":"Mov Disord"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0070","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1523\/JNEUROSCI.21-08-02889.2001","article-title":"Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration","volume":"21","author":"Kirik","year":"2001","journal-title":"J Neurosci"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0075","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/brain\/123.7.1365","article-title":"Embryonic ventral mes-encephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson\u2019s disease","volume":"123","author":"Lee","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0080","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/mds.22495","article-title":"Randomized controlled trial of memantine in dementia associated with Parkinson\u2019s disease","volume":"24","author":"Leroi","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0085","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nrd1958","article-title":"Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond","volume":"5","author":"Lipton","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0090","first-page":"2003","article-title":"Memantine can relieve certain symptoms in Parkinson disease. Improvement achieved in two out of three described cases with dyskinesia and cognitive failure","volume":"101","author":"L\u00f6kk","year":"2004","journal-title":"Lakartidningen"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0095","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/1531-8257(200009)15:5<873::AID-MDS1017>3.0.CO;2-I","article-title":"Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson\u2019s disease","volume":"15","author":"Luginger","year":"2000","journal-title":"Mov Disord"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0100","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","article-title":"Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson\u2019s disease","volume":"15","author":"Lundblad","year":"2002","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0105","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.expneurol.2005.02.002","article-title":"Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia","volume":"194","author":"Lundblad","year":"2005","journal-title":"Exp Neurol"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0110","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejphar.2013.04.054","article-title":"Modulation of NMDA receptor at the synapse: promising therapeutic interventions in disorders of the nervous system","volume":"719","author":"Mellone","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0115","first-page":"273","article-title":"Effect of memantine (NMDA antagonist) on Parkinson\u2019s disease: a double-blind crossover randomized study","volume":"22","author":"Merello","year":"1999","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0120","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/archneur.56.11.1383","article-title":"Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study","volume":"56","author":"Metman","year":"1999","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0125","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1136\/jnnp-2012-303182","article-title":"Memantine for axial signs in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled pilot study","volume":"84","author":"Moreau","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0235","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1212\/WNL.0000000000000050","article-title":"Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial","volume":"82","author":"Ory-Magne","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0135","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0028-3908(99)00019-2","article-title":"Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist \u2013 a review of preclinical data","volume":"38","author":"Parsons","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0140","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-1-59745-529-9_2","article-title":"Memantine as an example of a fast, voltage-dependent, open channel N-methyl-d-aspartate receptor blocker","volume":"403","author":"Parsons","year":"2007","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0145","series-title":"The rat brain in stereotaxic coordinates","author":"Paxinos","year":"1998"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0150","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/BF02260076","article-title":"Efficacy of memantine, an NMDA antagonist, in the treatment of Parkinson\u2019s disease","volume":"4","author":"Rabey","year":"1992","journal-title":"J Neural Transm Park Dis Dement Sect"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0155","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/j.1460-9568.2004.03591.x","article-title":"Chronic L-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson\u2019s disease","volume":"20","author":"Robelet","year":"2004","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0160","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1177\/1073858411435129","article-title":"Diversity in NMDA receptor composition: many regulators, many consequences","volume":"19","author":"Sanz-Clemente","year":"2013","journal-title":"Neuroscientist"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0225","doi-asserted-by":"crossref","first-page":"e15298","DOI":"10.1371\/journal.pone.0015298","article-title":"Amantadine for dyskinesias in Parkinson\u2019s disease: a randomized controlled trial","volume":"5","author":"Sawada","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0230","series-title":"Intervention strategies for degeneration of dopamine neurons in parkinsonism: optimising behavioral assessment of outcome. Innovative models of CNS disease; from molecule to therapy","first-page":"131","author":"Schallert","year":"1999"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0175","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000119246","article-title":"The use of diurnal vigilance changes in the EEG to verify vigilance-enhancing effects of memantine in a clinical pharmacological study","volume":"33","author":"Schulz","year":"1996","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0180","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/00002826-198712000-00003","article-title":"Amantadine and motor fluctuations in chronic Parkinson\u2019s disease","volume":"10","author":"Shannon","year":"1987","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0185","first-page":"141","article-title":"Duration of amantadine benefit on dyskinesia of severe Parkinson\u2019s disease","volume":"75","author":"Thomas","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0190","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.nbd.2013.08.014","article-title":"5-Hydroxy-tryptophan for the treatment of l-DOPA-induced dyskinesia in the rat Parkinson\u2019s disease model","volume":"60","author":"Tronci","year":"2013","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0195","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/mds.22917","article-title":"NMDA antagonist memantine improves levodopa-induced dyskinesias and \u201con\u2013off\u201d phenomena in Parkinson\u2019s disease","volume":"25","author":"Varanese","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0200","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/jgs.12058","article-title":"Unexpected improvement in levodopa-induced dyskinesia and on-off phenomena after introduction of memantine for treatment of Parkinson\u2019s disease dementia","volume":"61","author":"Vidal","year":"2013","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0205","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nrd1311","article-title":"Memantine hydrochloride","volume":"3","author":"Witt","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.neuroscience.2014.01.042_b0210","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/mds.23034","article-title":"Long-term antidyskinetic efficacy of amantadine in Parkinson\u2019s disease","volume":"25","author":"Wolf","year":"2010","journal-title":"Mov Disord"}],"container-title":["Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452214000633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452214000633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T01:17:14Z","timestamp":1565140634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306452214000633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":42,"alternative-id":["S0306452214000633"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroscience.2014.01.042","relation":{},"ISSN":["0306-4522"],"issn-type":[{"value":"0306-4522","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}